Antibody which specifically reacts with human integrin A6B4
US10030071B2 · kind B2 · utility
0Cited by
10References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 5, 2014 |
| Grant date | Jul 24, 2018 |
| Priority date | — |
| Expiry date | Oct 28, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.